天美传媒

Landon Westfall, Ph.D., is a bacteriologist, virologist, immunologist and molecular biologist with 15 years of experience in researching medically-relevant pathogens at both pre-clinical and clinical levels. As associate director of Influenza, he is responsible for overseeing the influenza virology program, both in vitro and in vivo, at Southern Research. He leads the support effort for pre-clinical studies and clinical sample testing by designing and executing validations or qualifications for immunogenicity assays, and managing sample analysis in partnership with both commercial and government clients. In addition, Westfall has experience conducting GLP regulated general safety toxicology studies for newly discovered influenza vaccines in support of regulatory submissions to the FDA.

Prior to joining Southern Research in 2015, Westfall was principal investigator and study director at Lovelace Respiratory Research Institute, a BSL3+/ABSL3+ contract research organization, where he successfully conducted a GLP-compliant animal model qualification for an aerosolized Tier-1 Select Agent in nonhuman primates. He supervised and performed a broad range of procedures using novel and standard techniques and methods, including refining a number of animal models using both viral and bacterial species. Viral animal models were primarily mouse and ferret influenza models using seasonal, pandemic and highly pathogenic avian influenza strains. Influenza studies included testing new vaccine platforms and antivirals for efficacy on newly emerged and pandemic influenza strains.

Westfall is a member of the American Society of Microbiology. He earned his doctorate in medical microbiology from Texas Tech University (TTU) Health Sciences Center and his Bachelor of Science in biology from TTU.

Dr. Garc铆a-Sastre is a Professor in the Department of Microbiology and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative-strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative-strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative-strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non-structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system. His studies provided the first description and molecular analysis of a viral-encoded IFN antagonist among negative-strand RNA viruses.  These studies led to the generation of attenuated influenza viruses containing defined mutations in their IFN antagonist protein that might prove to be optimal live vaccines against influenza. His research has resulted in more than 480 scientific publications and reviews. Dr. Garc铆a-Sastre is the director of the Center for Research on Influenza Pathogenesis (CRIP), one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor of Journal of Experimental Medicine, is Editor of PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines and Influenza and Other Respiratory Diseases.  He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Texel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerink Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain.